MedTrace Logo

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

NCT04676360 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-03-13

Study results available
· View outcomes & findings →

Summary

In this research study is looking to see how safe and effective belantamab mafodotin is in relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma.

* This research study involves the study drug belantamab mafodotin.
* Belantamab mafodotin is an antibody-drug conjugate (ADC), which is the combination of an antibody (a protein that binds to cells) and a drug. It works by using the antibody portion to enter into the lymphoma cells, and then releasing the drug portion to kill the lymphoma cells.

Conditions

  • Relapsed Plasmablastic Lymphoma
  • Refractory Plasmablastic Lymphoma
  • Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

Interventions

DRUG

Belantamab Mafodotin

Belantamab mafodotin will be administered intravenously at calculated dose on day 1 of each 21-day cycle.

Sponsors & Collaborators

Principal Investigators

  • Jacob Soumerai, MD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2023-11-27
Completion
2024-11-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04676360 on ClinicalTrials.gov